Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
Aptevo Therapeutics Inc. (APVO)
Last aptevo therapeutics inc. earnings: 8/9 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aptevotherapeutics.com/investor-overview
Company Research
Source: GlobeNewswire
Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210 Appear to be Safe and Well Tolerated at Doses Equivalent to IL-10 Doses that Generated a Clinical Effectin Competitor IL-10 Clinical Studies No Anti-drug Antibodies Observed in APVO210 SAD Phase 1 StudyBased on Patient Samples Obtained to Date APVO436 Phase 1 Clinical Study Progressing on Track;Approval Received to Begin Dosing in Cohort 4 SEATTLE, July 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has completed dosing in a single ascending dose (SAD) Phase 1 study of APVO210, a novel investigational bispecific antibody candidate being developed for the treatment of autoimmune diseases. Preliminary data from the SAD study show that sin
Show less
Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APVO alerts
High impacting Aptevo Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
APVO
News
- Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Aptevo Therapeutics Announces Closing of $4.6 Million Public OfferingAccesswire
- Aptevo Therapeutics Provides Pipeline Update [Yahoo! Finance]Yahoo! Finance
APVO
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- APVO's page on the SEC website